The open access article “European collaboration on relative effectiveness assessments: What is needed to be successful?” (Kleijnen S, et al. Health Policy (2015)), sets out to identify the possible barriers and success factors for the implementation of European collaboration on REAs of drugs.
The Joint Assessment of WP5 Strand A on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma is now available.
The joint rapid assessment of WP5 Strand A evaluates ‘sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine’ is available.
A page dedicated to the national uptake of the EUnetHTA’s outputs is now available.
Meeting minutes from the EUnetHTA-EMA meeting that took place 9 December 2014 in Diemen, the Netherlands is now available.